Ligand forges $21M licensing pact with CURx; Oxford BioMedica wins regenerative medicines funding competition;

@FierceBiotech: FDA's former IT boss nails down industry gig. Report from FierceBiotechIT.com | Follow @FierceBiotech

@JohnCFierce: MannKind soars after inhaled Afrezza delivers positive PhIII results. Report | Follow @JohnCFierce

@RyanMFierce: Fate Therapeutics, founded by stem cell experts, targets $69 million IPO. Article | Follow @RyanMFierce

> Ligand Pharmaceuticals ($LGND) struck a global licensing pact with CURx Pharmaceuticals for the development and commercialization of Ligand's Captisol-enabled Topiramate Injection for partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients. Under the terms of the agreement, Ligand is eligible for more than $21 million in potential net milestone payments and net royalties on future sales of 6.0% to 7.5%. Release

> Oxford BioMedica says it is one of 7 companies to win funding under the 2013 Supporting Regenerative Medicines and Cell Therapies competition. Release

Pharma News

@FiercePharma: With Pfizer, Novartis out, Amgen faces 1 possible rival for Onyx, per Bloomberg: AstraZeneca. Article | Follow @FiercePharma

@EricPFierce: India's Aurobindo buys, boosts capacity in sterile injectables, a hot market. Story from FiercePharmaManufacturing.com | Follow @EricPFierce

@CarlyHFierce: Here's the release on Boehringer earnings - BI says Pradaxa, Trajenta, Spiriva driving growth. Release | Follow @CarlyHFierce

> Tivicay marks beginning of end in growth of HIV branded market, EP says. Story

> China sales rep says Novartis ordered her to bribe doctors. Report

> New Novartis chair Reinhardt embarks on strategic review. Are divestments next? More

Medical Device News

@FierceMedDev: Bard's fate hangs with jury in latest vaginal mesh lawsuit. Article | Follow @FierceMedDev

@DamianFierce: Quintiles is buying Novella with its eye on emerging biotechs. News from FierceCRO.com | Follow @DamianFierce

@MarkHFierce: For LumiQuick, is it another case of regulators trying to assert control over a surging Dx industry? Item | Follow @MarkHFierce

> How did Israel become a hotbed for medical devices? Feature

> FDA sticks 'deadly' tag on Nova's glucose test strips. Report

> Accellent grows revenue but losses widen. Story

> Myriad soars despite rise of rivals. Article

Drug Delivery News

@MichaelGFierce: Virus-killing nanoviricides win orphan status for dengue fever. Story | Follow @MichaelGFierce

> Receptor-targeted antifolate drugs yield fewer side effects. More

> Bind files $80M IPO to support PhII nanotech cancer drug delivery. News

> 'Smart' DNA-based nanomeds self-assemble to release cancer drug. Story

> MannKind's inhaled insulin delivery tech passes PhIII trial. Article

> NanoMedical Systems snags $2.3M to develop drug-releasing implant. Item

And Finally… A new mouse study shows that adding sugar to your diet could prove quite toxic. Story

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.